Section Arrow
VKTX.NASDAQ
- Viking Therapeutics
Quotes are at least 15-min delayed:2026/10/20 23:10 EDT
Regular Hours
Last
 26.71
+1.66 (+6.63%)
Day High 
26.92 
Prev. Close
25.05 
1-M High
43.1 
Volume 
4.66M 
Bid
26.74
Ask
26.88
Day Low
25 
Open
25.1 
1-M Low
24.94 
Market Cap 
3.19B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 27.12 
20-SMA 30.66 
50-SMA 31.99 
52-W High 43.15 
52-W Low 24.94 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.67/-5.57
Enterprise Value
3.19B
Balance Sheet
Book Value Per Share
3.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
MRNAModerna242.08+15.19+6.69%-- 
IBRXImmunityBio8.77+0.35+4.16%-- 
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.